Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.65 |
| ▸ | MIF | P14174 | 5/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | STK17B | O94768 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Drinidene SCHEMBL2188657 | 1.00 | MAOA (0.65) | MAOAMIFMAOBKDM4EMEN1 | |
| Drinidene SCHEMBL2188660 | 1.00 | MAOA (0.65) | MAOAMIFMAOBKDM4EMEN1 | |
| Drinidene SCHEMBL28279862 | 0.96 | CYP19A1 (0.61) | MAOAMIFMAOBKDM4EMEN1 | |
| SCHEMBL2319027 | 0.85 | MAOA (0.90) | MAOAMIFMAOBKDM4EMEN1 | |
| SCHEMBL10673520 | 0.83 | MAOA (0.50) | MAOAMIFMAOBKDM4EMEN1 | |
| Anthrone SCHEMBL28117197 | 0.81 | MAOA (0.90) | MAOAMIFMAOBKDM4EMEN1 | |
| Anthrone SCHEMBL29448801 | 0.80 | MAOA (1.00) | MAOAMIFMAOBKDM4EMEN1 | |
| Anthrone SCHEMBL1527782 | 0.80 | MAOA (1.00) | MAOAMIFMAOBKDM4EMEN1 | |
| Anthrone SCHEMBL29357010 | 0.80 | MAOA (1.00) | MAOAMIFMAOBKDM4EMEN1 | |
| Anthrone SCHEMBL18143 | 0.80 | MAOA (1.00) | MAOAMIFMAOBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-4719353-A1 | REVERSIBLE SURFACTANT AND MULTIFUNCTIONAL DRUG DELIVERY SYSTEMS BASED THEREON | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025109604-A1 | DOLASTATIN 10 ANALOGS | Ariel Scientific Innovations Ltd. (IL) | 2025-05-30 | — | — | WO | disclosed |
| US-20250152319-A1 | ORAL APPLIANCE FOR DELIVERY OF MEDICAMENTS AND/OR OTHER SUBSTANCES | Emanate Biomedical, Inc. (US) | 2025-05-15 | — | — | US | disclosed |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250049928-A1 | ANESTHETIC PRODRUGS AND DERIVATIVES THEREOF FOR PROLONGED SENSORY SELECTIVE NERVE BLOCKAGE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2025-02-13 | — | — | US | disclosed |
| EP-4051691-B1 | DOLASTATIN 10 ANALOG | ARIEL SCIENT INNOVATIONS LTD (IL) | 2025-02-12 | — | — | EP | disclosed |
| US-20250032221-A1 | ORTHODONTIC DEVICES FOR DELIVERY OF AN ACTIVE AGENT | Smylio Inc. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12207984-B2 | Oral appliance for delivery of medicaments and/or other substances | Emanate Biomedical, Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3689357-B1 | COMPOSITIONS FOR CELLULAR RESTORATION AND METHODS OF MAKING AND USING SAME | ADVANCED REGEN MEDICAL TECH LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000040604-A2 | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049928-A1 | ANESTHETIC PRODRUGS AND DERIVATIVES THEREOF FOR PROLONGED SENSORY SELECTIVE NERVE BLOCKAGE | TRPV1, OPRL1, TRPA1 | MAOA 1291/4885MIF 4207/4885MAOB 394/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | MAOA 4803/4885MIF 1215/4885MAOB 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.